Status:
TERMINATED
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
The Matthew Larson Foundation for Pediatric Brain Tumors
Conditions:
Medulloblastoma
Eligibility:
All Genders
3-18 years
Phase:
EARLY_PHASE1
Brief Summary
Participants enrolling on this study will receive standard of care chemotherapy for Wnt positive medulloblastoma without the radiation therapy or the weekly chemotherapy that is given during radiation...
Detailed Description
There will be 9 cycles of chemotherapy. There are two different kinds of cycles given. They are referred to as A and B. Cycle A lasts for 6 weeks and Cycle B lasts for 4 weeks. B cycles are given aft...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Participants must have classical histology posterior fossa medulloblastoma as determined by institutional neuro-pathological evaluation.
- Sufficient pathologic material must be available for central analysis and review
- Tumors will be deemed Wnt positive if, at the time of central analysis, there is:
- Monosomy 6 as determined by array CGH
- Gene transcript detection by NanoString supporting Wnt+ medulloblastoma
- Absence of large-cell, anaplastic histology
- Nuclear b-catenin IHC will be determined, but not required for the diagnosis
- Absence of residual or disseminated disease as defined by the following criteria: Minimal residual disease as determined by post-operative imaging preferably performed within 48 hours of resection (and at most 28 days post-surgery), i.e. gross total resection or residual disease of \<1.5cm2 on post-operative imaging.
- No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF). Assessments must include MRI imaging of the brain and spine with and without contrast and a lumbar puncture for CSF cytology
- Diagnostic imaging (pre and post contrast) must be forwarded to Dana-Farber Cancer Institute (DFCI) for central review to confirm eligibility
- Patients must not have had any radiation therapy or chemotherapy for medulloblastoma prior to study enrollment
- Patients must have a Lansky performance status of \>/=30 for children \</=10 years of age or a Karnofsky performance status of \> 30 for children \> 10 years of age.
- Participants must have normal organ and marrow function as defined below:
- Hemoglobin greater than 10 g/dL (can be transfused). Hemoglobin \<10 g/dL due to operative blood loss is permitted.
- Absolute neutrophil count \> 1.0x109/L
- Platelets \> 100,000/uL (non-transfused)
- Total bilirubin \<1.5 x upper limit normal
- SGOT (AST) or SGPT (ALT) \<2.5 x upper limit normal (ULN) for age
- Creatinine clearance or radioisotope GFR \>70 ml/min/1.73m2 or normal serum creatinine for patient's age and gender
- All females of child-bearing age must have a negative pregnancy test before being enrolled on study. All patients of child-bearing age must practice an effective method of birth control whilst undergoing chemotherapy on study.
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, lomustine, vincristine or cyclophosphamide.
Exclusion
Key Trial Info
Start Date :
April 4 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2018
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT02212574
Start Date
April 4 2017
End Date
November 9 2018
Last Update
November 5 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Childrens Hospital Hematology/Oncology
Phoenix, Arizona, United States, 85016-7710
2
Children's Hospital Colorado Center for Cancer & Blood Disorders
Aurora, Colorado, United States, 80045
3
M D Anderson Cancer Center-Orlando Pediatric Hematology/Oncology
Orlando, Florida, United States, 32806
4
All Children's Hospital Pediatric Hematology/Oncology
St. Petersburg, Florida, United States, 33701